Annals of Clinical and Translational Neurology (May 2021)

Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis

  • Audrey Gauthier,
  • Sébastien Viel,
  • Magali Perret,
  • Guillaume Brocard,
  • Romain Casey,
  • Christine Lombard,
  • Sabine Laurent‐Chabalier,
  • Marc Debouverie,
  • Gilles Edan,
  • Sandra Vukusic,
  • Christine Lebrun‐Frénay,
  • Jérôme De Sèze,
  • David Axel Laplaud,
  • Giovanni Castelnovo,
  • Olivier Gout,
  • Aurélie Ruet,
  • Thibault Moreau,
  • Olivier Casez,
  • Pierre Clavelou,
  • Eric Berger,
  • Hélène Zephir,
  • Sophie Trouillet‐Assant,
  • Eric Thouvenot,
  • OFSEP Investigators

DOI
https://doi.org/10.1002/acn3.51355
Journal volume & issue
Vol. 8, no. 5
pp. 1141 – 1150

Abstract

Read online

Abstract We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The EllaTM instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to EllaTM results. As for SimoaTM, serum neurofilament‐light chain levels measured by EllaTM were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.